No Data
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$17,597.91 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 8,288 shares of common stock on Jul 1, 2024 at an average price of $2.1233 for a total value of $17,597.91.Source: Announce
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$142.5K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 64,568 shares of common stock on Jun 27, 28, 2024 at an average price of $2.207 for a total value of $142.5K.Source: Announ
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$28,734.32 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 12,725 shares of common stock on Jun 25, 2024 at an average price of $2.2581 for a total value of $28,734.32.Source: Announ
Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics
Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase during
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$44,007.97 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 15,054 shares of common stock on May 30, 31, 2024 at an average price of $2.9233 for a total value of $44,007.97.Source: An